Bispecific antisense oligonucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
CA 2469685 C · Owner: Gleave, Martin · Inventors: Signaevsky, Maxim; Gleave, Martin
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Bispecific antisense oligonucleotides which consist essentially of a sequence of bases that is complementary to portions of both the gene encoding human IGFBP-2 and the gene encoding human IGFBP-5 are useful in as antisense therapeutics in the treatment of endocrine-regulated cancers.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 17, 2003 and granted March 12, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 17, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 17, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.